Literature DB >> 32195022

Histone demethylase KDM4C activates HIF1α/VEGFA signaling through the costimulatory factor STAT3 in NSCLC.

Xiaowei Wu1, Yu Deng1, Yukun Zu1, Jin Yin2.   

Abstract

Tumor development is accompanied by high hypoxia and a dense network of immature vessels. The hypoxia-inducible factor/vascular endothelial growth factor (HIF/VEGF) signaling pathway is activated in various solid tumors. It is thought that HIF/VEGF signaling activation results from intratumoral hypoxia partly. Multiple studies have reported that VEGF is a common target gene for both transcription factors STAT3 and HIF1. KDM4C has also been reported to function as a co-activation factor for HIF-1β/VEGF signaling activation. In this manuscript. Our results demonstrate that KDM4C promotes NSCLC tumor angiogenesis by transcriptionally activating HIF1α/VEGFA signaling pathway. We also find that STAT3 functions as a costimulatory factor in this process. This pathway opens a potential therapeutic window for the treatment of NSCLC. AJCR
Copyright © 2020.

Entities:  

Keywords:  HIF1α; KDM4C; NSCLC; STAT3; Tumor angiogenesis

Year:  2020        PMID: 32195022      PMCID: PMC7061751     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  23 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A.

Authors:  Imari Mimura; Masaomi Nangaku; Yasuharu Kanki; Shuichi Tsutsumi; Tsuyoshi Inoue; Takahide Kohro; Shogo Yamamoto; Takanori Fujita; Teppei Shimamura; Jun-ichi Suehiro; Akashi Taguchi; Mika Kobayashi; Kyoko Tanimura; Takeshi Inagaki; Toshiya Tanaka; Takao Hamakubo; Juro Sakai; Hiroyuki Aburatani; Tatsuhiko Kodama; Youichiro Wada
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

3.  Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.

Authors:  Melanie Wissmann; Na Yin; Judith M Müller; Holger Greschik; Barna D Fodor; Thomas Jenuwein; Christine Vogler; Robert Schneider; Thomas Günther; Reinhard Buettner; Eric Metzger; Roland Schüle
Journal:  Nat Cell Biol       Date:  2007-02-04       Impact factor: 28.824

4.  VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.

Authors:  Haibo Wang; Grace Byfield; Yanchao Jiang; George Wesley Smith; Manabu McCloskey; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2012-01-09       Impact factor: 4.307

Review 5.  Hypoxia and hypoxia-inducible factors: master regulators of metastasis.

Authors:  Xin Lu; Yibin Kang
Journal:  Clin Cancer Res       Date:  2010-10-20       Impact factor: 12.531

6.  Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.

Authors:  Johnathan R Whetstine; Amanda Nottke; Fei Lan; Maite Huarte; Sarit Smolikov; Zhongzhou Chen; Eric Spooner; En Li; Gongyi Zhang; Monica Colaiacovo; Yang Shi
Journal:  Cell       Date:  2006-04-06       Impact factor: 41.582

7.  Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.

Authors:  Weibo Luo; Ryan Chang; Jun Zhong; Akhilesh Pandey; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

Review 8.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

9.  Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth.

Authors:  Brittany L Gregory; Vivian G Cheung
Journal:  Genome Res       Date:  2013-11-27       Impact factor: 9.043

10.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more
  2 in total

1.  Resveratrol Suppresses Tumor Progression via Inhibiting STAT3/HIF-1α/VEGF Pathway in an Orthotopic Rat Model of Non-Small-Cell Lung Cancer (NSCLC).

Authors:  Huixia Wang; Ruzhen Jia; Tianle Lv; Mei Wang; Shiwei He; Xia Zhang
Journal:  Onco Targets Ther       Date:  2020-07-21       Impact factor: 4.147

2.  Nephrotoxicity of perfluorooctane sulfonate (PFOS)-effect on transcription and epigenetic factors.

Authors:  Yi Wen; Faizan Rashid; Zeeshan Fazal; Ratnakar Singh; Michael J Spinella; Joseph Irudayaraj
Journal:  Environ Epigenet       Date:  2022-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.